AstraZeneca (GB:AZN) has released an update.
AstraZeneca has reported a solid performance in H1 2024, with an 18% increase in Total Revenue to $25,617m, spurred by robust Product Sales growth and Alliance Revenue. The company has seen significant growth across various therapy areas, leading to a 5% rise in Core EPS to $4.03, despite lower gains compared to the previous year. Based on these results, AstraZeneca confidently upgrades its FY 2024 guidance, projecting mid-teens percentage growth in both Total Revenue and Core EPS at constant exchange rates.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
